The purpose of the present study was to explore the usefulness of the Mexican
sequential organ failure assessment (MEXSOFA) score for assessing the risk of
mortality for critically ill patients in the ICU. A total of 232 consecutive
patients admitted to an ICU were included in the study. The MEXSOFA was
calculated using the original SOFA scoring system with two modifications: the
PaO2/FiO2 ratio was replaced with the
SpO2/FiO2 ratio, and the evaluation of neurologic
dysfunction was excluded. The ICU mortality rate was 20.2%. Patients with an
initial MEXSOFA score of 9 points or less calculated during the first 24 h after
admission to the ICU had a mortality rate of 14.8%, while those with an initial
MEXSOFA score of 10 points or more had a mortality rate of 40%. The MEXSOFA
score at 48 h was also associated with mortality: patients with a score of
9 points or less had a mortality rate of 14.1%, while those with a score of
10 points or more had a mortality rate of 50%. In a multivariate analysis, only
the MEXSOFA score at 48 h was an independent predictor for in-ICU death with an
OR = 1.35 (95%CI = 1.14-1.59, P < 0.001). The SOFA and MEXSOFA scores
calculated 24 h after admission to the ICU demonstrated a good level of
discrimination for predicting the in-ICU mortality risk in critically ill
patients. The MEXSOFA score at 48 h was an independent predictor of death; with
each 1-point increase, the odds of death increased by 35%.
Influenza A (H1N1pdm09)-related critical illness still predominantly affects relatively young to middle-aged patients and is associated with severe hypoxemic respiratory failure. The local critical care system and available resources may be influential determinants of patient outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.